COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY

被引：0
|
作者：
Darba, J. [1 ]
Kaskens, L. [2 ]
Sanchez-de la Rosa, R. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth, Barcelona, Spain
[3] TEVA Pharma, Madrid, Spain
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A623 / A623
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence
    Graham, J. B.
    Earnshaw, S. R.
    Castelli-Haley, J.
    Oleen-Burkey, M.
    Johnson, K. P.
    VALUE IN HEALTH, 2007, 10 (06) : A381 - A381
  • [32] Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Vestri, Giulia
    Giuliani, Luigi
    Canonico, Pier Luigi
    Centonze, Diego
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 : 13 - 36
  • [33] Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis
    Reder, Anthony T.
    Arndt, Nancy
    Roman, Cortnee
    Geremakis, Caroline
    Mendoza, Jason P.
    Su, Ray
    Makin, Charles
    Avila, Robin L.
    Vignos, Megan C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [34] Baseline demographics of a randomised study comparing interferon beta-1a with glatiramer acetate in treating relapsing-remitting multiple sclerosis, using McDonald criteria for inclusion: the REGARD study
    Mikol, D.
    Barkhof, F.
    Coyle, P.
    Jeffery, D.
    Uitdehaag, B.
    Kim, R.
    Rodriguez, S.
    Schwid, S.
    MULTIPLE SCLEROSIS, 2006, 12 : S208 - S209
  • [35] A cost-effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy
    Gani, R.
    Samuels, E. R.
    Hughes, S.
    Giovanonni, G.
    VALUE IN HEALTH, 2008, 11 (03) : A140 - A140
  • [36] Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
    Sanchez-de la Rosa, Rainel
    Garcia-Bujalance, Laura
    Meca-Lallana, Jose
    HEALTH ECONOMICS REVIEW, 2015, 5
  • [37] Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
    Rainel Sánchez-de la Rosa
    Laura García-Bujalance
    José Meca-Lallana
    Health Economics Review, 5
  • [38] The REGARD trial: safety and immunogenicity from a randomized, assessor-blinded trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis
    Coyle, P. K.
    Barkhof, F.
    Chang, F.
    Jeffery, D. R.
    Mikol, D. D.
    Stubinski, B.
    Schwid, S.
    Uitdehaag, B. M. J.
    MULTIPLE SCLEROSIS, 2007, 13 : S270 - S270
  • [39] The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Hua, Le H.
    Hersh, Carrie M.
    Morten, Peter
    Kusel, Jeanette
    Lin, Feng
    Cave, Julie
    Varga, Stefan
    Herrera, Vivian
    Ko, John J.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (04): : 490 - +
  • [40] Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
    Khatri, Bhupendra
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kappos, Ludwig
    Montalban, Xavier
    Pelletier, Jean
    Stites, Tracy
    Wu, Stacy
    Holdbrook, Fred
    Zhang-Auberson, Lixin
    Francis, Gordon
    Cohen, Jeffrey A.
    Cohen, J.
    Barkhof, F.
    Comi, G.
    Hartung, H.P.
    Khatri, B.
    Montalban, X.
    Pelletier, J.
    Easton, D.
    Calandra, T.
    DiMarco, J.
    Hudson, L.
    Kesselring, J.
    Laupacis, A.
    Temkin, N.
    Weinshenker, B.
    Zarbin, M.
    Barkhof, F.
    Poppe, P.
    Luetic, G.
    Cristiano, E.
    Caceres, F.
    Garcea, O.
    Correale, J.
    Ballario, C.
    Piedrabuena, R.
    Pollard, J.
    Beran, R.
    Hodgkinson, S.
    Schwartz, R.
    Heard, R.
    King, J.
    Butzkueven, H.
    Maida, E.M.
    Vass, K.
    Franta-Elmer, C.
    Berger, T.
    Aichner, F.
    LANCET NEUROLOGY, 2011, 10 (06): : 520 - 529
12345